Cytek Biosciences. (Nasdaq: CTKB) to Showcase Full Spectrum Profiling Technology at Major Clinical Events

3 min read | September 19, 2024 01:52 AM PDT | By Team Kalkine Media

Google News:

Cytek Biosciences. (Nasdaq: CTKB) to Showcase Full Spectrum Profiling Technology at Major Clinical Events — Image source: @Darko Stojanovic/Pixabay

Recent News

Trane Technologies (NYSE:TT) Draws Fresh ESG Spotlight

Phillips 66 (NYSE:PSX) Valuation Buzz Turns Energy Eyes Sharper

Lowe’s Companies (NYSE:LOW) Brand Push Gets Louder

Is Ciena (NYSE:CIEN) Leading The Next Wave of AI-Powered 5G?

Make Kalkine Media
My Trusted Source

Cytek Biosciences, Inc. (Nasdaq:CTKB) is poised to enhance its global footprint by participating in key clinical industry events, showcasing its innovative Full Spectrum Profiling™ (FSP™) technology. The company’s commitment to advancing cell analysis will be prominently featured at the European Society for Clinical Cell Analysis (ESCCA) 2024 Conference in September and the 39th International Clinical Cytometry (ICCS) Meeting & Course in October.

Dr. Wenbin Jiang, CEO of Cytek Biosciences, expressed the company’s vision: “We aim to bring our Full Spectrum Profiling technology to more labs, enhancing accuracy of results and lab productivity.” This ambition aligns with Cytek's mission to transform cell analysis, ultimately benefiting healthcare diagnostics and research.

At the ESCCA 2024, taking place from September 25-28 in Palma de Mallorca, Spain, Cytek will demonstrate its comprehensive cell analysis solutions. The conference is a critical gathering for professionals focused on advancing clinical cell analysis practices, promoting innovation, and improving diagnostic and therapeutic outcomes. One of the highlights will be a symposium led by Dr. Nicholas McCarthy from the University of Birmingham, focusing on optimizing acute myeloid leukemia minimal residual disease (AML-MRD) analysis. He will present a 21-color antibody panel designed for the Cytek® Northern Lights™- CLC flow cytometer on Thursday, September 26, from 3:00-3:30 p.m. local time.

Following this, Cytek will also participate in the ICCS Annual Meeting & Course in Seattle, a platform dedicated to education and collaboration in clinical cytometry. This event aims to enhance professionals' skills through workshops and presentations that foster innovation in diagnosing and monitoring diseases like cancer and immunodeficiencies. Cytek will host a "Lunch and Learn" session on October 6, 2024, at 12:00 p.m. PT, presented by Dr. David Ng, director of Flow Cytometry and Applied AI at ARUP Laboratories.

Dr. Ng highlighted the transformative impact of spectral flow cytometry, stating, “The integration of spectral flow cytometry into our workflows has been a game-changer for our resource-limited and space-constrained laboratories. Transitioning from traditional 10-color panels to a single tube panel significantly reduces reagent consumption and streamlines processes, allowing our technologists to focus on high-value tasks like analysis. These efficiency gains directly translate into faster, more useful results.”

Through these events, Cytek Biosciences aims to lead the conversation in clinical cell analysis, highlighting how FSP technology can drive efficiency and accuracy in laboratories worldwide. As the company continues to innovate, its participation in these conferences underscores its dedication to enhancing healthcare outcomes through advanced scientific solutions.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.